Search
Research
Prospects for the future: supporting the elimination of rheumatic heart disease – a National Heart, Lung, and Blood Institute Workshop ProceedingsJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@
Research
Research priorities for the primordial prevention of acute rheumatic fever and rheumatic heart disease by modifying the social determinants of healthThe social determinants of health such as access to income, education, housing and healthcare, strongly shape the occurrence of acute rheumatic fever and rheumatic heart disease at the household, community and national levels.
Research
Tertiary prevention and treatment of rheumatic heart disease: a National Heart, Lung, and Blood Institute working group summaryAlthough entirely preventable, rheumatic heart disease, a disease of poverty and social disadvantage resulting in high morbidity and mortality, remains an ever-present burden in low-income and middle-income countries and rural, remote, marginalised and disenfranchised populations within high-income countries.
Research
Surgery for rheumatic heart disease in the Northern Territory, Australia, 1997-2016: what have we gained?Between 1964 and 1996, the 10-year survival of patients having valve replacement surgery for rheumatic heart disease (RHD) in the Northern Territory, Australia, was 68%. As medical care has evolved since then, this study aimed to determine whether there has been a corresponding improvement in survival.
Research
Rheumatic heart disease in Timor-Leste school students: an echocardiography-based prevalence studyThe rates of RHD in Timor-Leste are among the highest in the world, and prevalence is higher among girls than boys. Community engagement is essential for ensuring follow-up and the effective delivery of secondary prophylaxis.
Research
Clinical outcomes for young people with screening-detected and clinically-diagnosed rheumatic heart disease in FijiYoung people with screening-detected RHD have worse health outcomes than screen-negative cases in Fiji.
Research
Benzathine penicillin G for the management of RHD: Concerns about quality and access, and opportunities for intervention and improvementBenzathine penicillin G is an important antibiotic for the treatment and prevention of group A streptococcal infections associated with rheumatic fever and...
Research Theme
First Nations Health and EquityAboriginal health is everyone's business. The needs of Aboriginal and Torres Strait Islander families and kids is integrated into all relevant areas of our work. Improving the health and wellbeing of Aboriginal and Torres Strait Islander kids and families is an overarching priority for every team at The Kids.
Research
Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilisAlthough benzylpenicillin (penicillin G) is listed by the World Health Organization as an Essential Medicine, dose optimization is a persistent challenge, especially for long-acting intramuscular formulations. Maintaining sustained antibiotic exposure at target concentrations is crucial for secondary chemoprophylaxis of rheumatic heart disease and treatment of syphilis.
Research
Severe adverse reactions to benzathine penicillin G in rheumatic heart disease: A systematic review and meta-analysisFear of severe adverse reaction (SAR) and reluctance of health care providers to administer intramuscular injections are major contributing factors to poor adherence of benzathine penicillin G (BPG) in the management of rheumatic heart disease (RHD). However, data on the risk of SARs following BPG injections for RHD are relatively limited and inconclusive. Our systematic review and meta-analysis aimed to evaluate the incidence of SARs associated with BPG injections used for secondary prophylaxis of RHD.